Joint Domestic Sales and Marketing of Six Oral Diabetes Treatments to Begin in January 2027
Boryung Pharma Solution, Set to Launch in 2027, to Expand Diabetes Treatment Portfolio

Boryung and Celltrion Pharm announced on November 16 that they had signed an agreement to jointly sell the Nesina and Actos product lines, treatments for type 2 diabetes.


Starting in January 2027, the two companies will jointly handle domestic sales and marketing for six oral diabetes treatments: ▲Nesina Tablets (alogliptin) ▲Nesina Met Tablets (alogliptin and metformin) ▲Nesina Met Extended-Release Tablets (alogliptin and metformin) ▲Actos Tablets (pioglitazone) ▲Actos Met Tablets (pioglitazone and metformin) ▲Nesina Act Tablets (alogliptin and pioglitazone).


At the signing ceremony for the joint promotion and exclusive sales and distribution agreement for Nesina and Actos, held on the 16th at Celltrion Pharm’s Gwacheon office, Jeong Woongje, head of sales at Boryung (left), and Yoo Youngho, CEO of Celltrion Pharm (right), pose for a commemorative photo. Boryung

At the signing ceremony for the joint promotion and exclusive sales and distribution agreement for Nesina and Actos, held on the 16th at Celltrion Pharm’s Gwacheon office, Jeong Woongje, head of sales at Boryung (left), and Yoo Youngho, CEO of Celltrion Pharm (right), pose for a commemorative photo. Boryung

View original image

Nesina is an original drug containing alogliptin, a DPP-4 inhibitor. It received approval from the U.S. Food and Drug Administration (FDA) in 2013. Actos contains pioglitazone, a TZD that improves insulin resistance, and received FDA approval in 1999. Nesina Act, a combination drug containing both ingredients, received FDA approval in 2013.


Celltrion Pharm acquired the Nesina and Actos product lines from Takeda in 2020. According to UBIST, a pharmaceutical market research firm, domestic prescription sales totaled 51.7 billion won in 2025. The product line includes both single-ingredient and combination drugs, allowing prescriptions to be tailored to patients' conditions and stages of treatment, the companies said.


The two companies plan to combine their sales and marketing capabilities and product competitiveness to strengthen the Nesina and Actos product lines' position in the domestic market.


The agreement is also expected to support the expansion of Boryung's diabetes business at Boryung Pharma Solution, its sales and marketing subsidiary scheduled to launch in 2027. Boryung sells Truberdy, a combination drug containing dapagliflozin and pioglitazone, and Trudapa, a single-ingredient dapagliflozin drug. By adding original drugs in the DPP-4 inhibitor and TZD classes, the company will expand its diabetes treatment portfolio. Boryung Pharma Solution will use this portfolio to strengthen sales and marketing in the diabetes treatment area.


Celltrion Pharm CEO Yoo Youngho said, "The two companies have joined forces based on the experience they have built in the domestic diabetes treatment market. Together with Boryung, we will provide healthcare professionals with comprehensive information about the Nesina and Actos product lines and contribute to effective treatment for patients with type 2 diabetes and improvements in their quality of life."



Boryung Vice President Jeong Woongje, who is set to lead Boryung Pharma Solution, said, "By adding Celltrion Pharm's diabetes treatments Nesina and Actos, we have strengthened Boryung's diabetes treatment portfolio. We will build on our existing sales network to expand our position in the market." He added, "We will draw on Boryung Pharma Solution's sales and marketing expertise to communicate the value of these products to healthcare professionals and create new momentum for their growth."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing